Nureca Share Price Hit 5% Upper Circuit as Board to Consider Buyback on November 28

On November 25, 2025, Nureca informed the stock exchanges that its board will consider a buyback proposal on November 28, 2025. The earlier meeting set for November 10, 2025, was postponed due to the unavailability of most Independent Directors. 

Background on the Postponed Board Meeting 

The company stated that the earlier meeting to consider the buyback proposal was deferred as the majority of Independent Directors were unavailable. The postponement was communicated through a filing dated November 5, 2025. The board will now revisit the matter in the upcoming meeting. 

A buyback allows a company to repurchase its shares, lowering the number of outstanding shares in the market. This can support EPS and stabilise the share price. Companies may pursue buybacks to manage surplus cash, address dilution or improve financial ratios. 

Nureca’s Business and Product Portfolio 

Nureca operates in the home healthcare and wellness sector with brands such as Dr Trust, Dr Physio and Trumom. As per the company, more than 1.24 crore Dr Trust products have been sold across 5 countries. The company’s portfolio covers chronic care, orthopaedic items, lifestyle products, nutrition, mother and baby care, and connected devices. 

Read More: A-1 Limited Share Price Hits 5% Upper Circuit as Shareholder Voting on Bonus Issue and Stock Split Begins! 

Nureca Share Price Performance 

As of November 26, 2025, at 11:48 AM, Nureca share price on BSE was ₹267.5 up by 4.98% from the previous closing price. 

Conclusion 

Nureca’s share price movement reflects market attention on the scheduled board meeting to review a buyback proposal on November 28, 2025. The development follows an earlier postponement and comes amid steady interest in the company’s healthcare and wellness offerings. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.